NCT00640276

Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome

A Prospective Comparative Clinical Study to Identify Efficacy and Safety of Pitavastatin in Patients With a Metabolic Syndrome

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 187 (actual)
• Sponsor: JW Pharmaceutical · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

We will identify the influence of long-term treatment of Pitavastatin compared to non-treatment control group on the metabolic syndrome by evaluation of a change of metabolic syndrome component score. And we will additionally observe the changes of CVD risk factors like lipid profile, abdominal fat, insulin resistance and so on.

Conditions

• Hypercholesterolemia
• Metabolic Syndrome

Interventions

Type	Name	Description
DRUG	pitavastatin	Pitavastatin 2mg daily once
BEHAVIORAL	Lifestyle Modification	conducting mainly exercises and diet

Timeline

• Start date: 2008-04-01
• Primary completion: 2011-02-01
• Completion: 2011-06-01
• First posted: 2008-03-21
• Last updated: 2012-03-30

Locations

2 sites across 1 country: South Korea